First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes
Written by
Cancer Network
Published
0
comments
0
min
The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.